Blog
CJC-1295 without DAC: a similar name is not matching evidence
No directly matching primary clinical paper was established in this search for the no-DAC product. This is an evidence-gap explainer, not a claim that all similar names share published results.
Evidence discussed: Related-formulation human evidence; direct-match gap.
What the researchers studied
The frequently cited 2006 paper studied a long-acting CJC-1295 formulation in two placebo-controlled trials. It reported sustained changes in growth hormone and IGF-I. [1]
How to interpret the result
That study must not be used as direct evidence for a product labelled no DAC. The long-acting design defines the cited intervention. Its exposure and duration cannot simply be transferred to a differently specified product.
What readers can take from it
No directly matching primary clinical paper was established in this search for the no-DAC product. This is an evidence-gap explainer, not a claim that all similar names share published results.
This original editorial summary provides no diagnosis, dosing or treatment advice. The study did not test or certify a PeptiKing product.
Source
[1] Teichman et al., long-acting CJC-1295 in adults (2006). PMID: 16352683. Based on the PubMed-indexed abstract and record; full-text methods were not independently reviewed.